Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002197 · ClinicalTrials.gov registry record · NA
A Study of 1592U89 in HIV-Infected Children
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
- 250
- Enrollment target
NCT00002197: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002197 is a NA study that has completed, run by Glaxo Wellcome. The registered enrollment target is 250 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002197, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available. The study also examines the effect 1592U89 has on the levels of HIV in the blood.
Interventions
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Phase | NA |
What the finished NCT00002197 record still lists
NCT00002197 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which Abacavir sulfate is the first listed.
NCT00002197 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002197 about?
NCT00002197 is a clinical study titled "A Study of 1592U89 in HIV-Infected Children". The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available. The study also examines the effect 1592U89 has on the levels of HIV in the blood.
What is the current status of trial NCT00002197?
This trial is currently completed. It is a NA study. The enrollment target is 250 participants.
What interventions are being tested in trial NCT00002197?
The interventions under investigation include: Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002197?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002197's enrollment target sits among peer trials
250 410th of 2000 higher than 1,567 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy